Meeting
2019 ASCO Annual Meeting
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
Authors
Lu Han
Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Lu Han , Quanli Gao , Keshu Zhou , Jian Zhou , Baijun Fang , Jishuai Zhang , Hongjian Li , Yongping Song
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03661554
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2535)
DOI
10.1200/JCO.2019.37.15_suppl.2535
Abstract #
2535
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
First Author: Yarong Liu
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
First Author: Xinfeng Chen
Poster
2017 ASCO Annual Meeting
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
First Author: Jesus G. Berdeja